English
Home > Products > CAS NO 132203-70-4

China CAS NO 132203-70-4 Factory

Our well-equipped facilities and excellent quality control throughout all stages of production enables us to guarantee total customer satisfaction for CAS NO 132203-70-4,132203-70-4,Cilnidipine API,Cilnidipine, We have experienced manufacturing facilities with more than 100 employees. So we can guarantee short lead time and quality assurance.
CAS NO 132203-70-4, We maintain long-term efforts and self-criticism, which helps us and improvement constantly. We strive to improve customer efficiency to save costs for customers. We do our best to improve the quality of product. We are going to not live up to the historic opportunity of the times.

Related Products

Hot Products

  • Thymosin α1

    Thymosin α1

    Product Name:Thymosin α1
    Molecular Formula:C129H215N33O55
    Molecular Weight;3108.32
    CAS Registry Number;62304-98-7/69440-99-9
  • 4-Bromo-1-methylpyrazole

    4-Bromo-1-methylpyrazole

    Product Name:4-Bromo-1-methylpyrazole
    Molecular Formula:C4H5BrN2
    Molecular Weight:161
    CAS Registry Number:15803-02-8
  • Diammonium glycyrrhizinate

    Diammonium glycyrrhizinate

    Product Name:Diammonium glycyrrhizinate
    Molecular Formula:C42H65NO16
    Molecular Weight;839.97
    CAS Registry Number;79165-06-3
  • alpha-Methylcinnamaldehyde

    alpha-Methylcinnamaldehyde

    Product Name:alpha-Methylcinnamaldehyde
    Molecular Formula:C10H10O
    Molecular Weight:146.19
    CAS Registry Number:101-39-3
  • 9,9-Dimethyl-2-iodofluorene

    9,9-Dimethyl-2-iodofluorene

    Product Name:9,9-Dimethyl-2-iodofluorene
    Molecular Formula:C15H13I
    Molecular Weight:320.17
    CAS Registry Number:144981-85-1
  • 2,4-Difluorobenzotrifluoride

    2,4-Difluorobenzotrifluoride

    Product Name:2,4-Difluorobenzotrifluoride
    Molecular Formula:C7H3F5
    Molecular Weight:182.09
    CAS Registry Number:64248-61-9
  • Related Blog
  • Reviews

  • Pharmaceutical Intermediates Manufacturers - Something You Need to Know About Pharma Intermediates Industry

    Pharmaceutical intermediates are actually chemical raw materials or chemical products that need to be used in the synthesis of drugs. Such chemical products can be produced in ordinary chemical plants without obtaining a pharmaceutical production license. As long as the technical indicators meet certain level requirements, they can be used to participate in the synthesis and production of drugs.

  • CAS 148553-50-8 What is Pregabalin?

    Pregabalin is an anti-epileptic drug, also called an anticonvulsant. It works by slowing down impulses within the brain that cause seizures. Pregabalin also affects chemicals within the brain that send pain signals across the systema nervosum.

  • How to find the best China API manufacturer?

    Active pharmaceutical ingredients or APIs can be defined as the chemicals used to manufacture pharmaceutical drugs. The active ingredient (AI) is the substance or substances that are biologically active within the drug and is the specific component responsible for the desired effect it has on the individual taking it.

  • What is an Active Pharmaceutical Ingredient (API in Pharma)?

    Sandoo Pharmaceutical is a professional active pharmaceutical intermediate manufacturer, producing high quality APIs. Sandoo Pharmaceutical provides a wide range of active pharmaceutical intermediates.

  • Differences Between Pharmaceutical Raw Materials, Excipients and Pharmaceutical Intermediates

    In the pharmaceutical industry, there are various names of raw materials, such as pharmaceutical raw materials, pharmaceutical intermediates and pharmaceutical excipients in the process of pharmaceutical production. This article will take everyone to recognize these three concepts.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept